📄 Recross-examination of Dr. John Gerdes (part 2) — Monday, August 7, 1995
Address:
C:\DEPT103\CRIMINAL\1995\AUG\7\RECROSS-EXAMINATION-OF-DR-JOHN.DOC
TRIAL
▲ Day 130 of 167

Recross-examination of Dr. John Gerdes (part 2)

Witness: Dr. John Gerdes
Examiner: George Clarke
Called by: Defense • Date: Monday, August 7, 1995 • Utterances: 312
Clarke completed his recross of Dr. Gerdes, pinning down that Gerdes believes PCR should not be used in forensics at all — not to include or exclude anyone — regardless of corroborating RFLP results. Scheck then rehabilitated Gerdes on several fronts: the impossibility of proving cross-contamination after the fact, the irrelevance of the C dot when interpreting mixtures, and the significance of newly introduced discovery documents (1315-A and 1315-B) showing that LAPD had initially blocked out contaminated strips before providing them in discovery. Clarke's further recross focused on whether the higher DNA concentration in back gate sample 117 could be explained by collection logistics rather than planting, and Scheck closed by having Gerdes confirm that no one knows when those stains were deposited or whether the blood contained EDTA.
1 (The following proceedings were held in open court, in the presence of the jury:)
2 THE COURT:

All right. Thank you, ladies and gentlemen. Please be seated. Dr. Gerdes. All right. Let the record reflect we've been rejoined by all the members of our jury panel. Dr. John Gerdes is again on the witness stand undergoing recross-examination by Mr. Clarke, who is about to conclude his recross-examination.

3 MR. CLARKE:

Thank you, your Honor.

4 THE COURT:

You're welcome.

5 MR. CLARKE:

Dr. Gerdes, just returning, if I could for a few moments, to the area of different levels of DNA in samples. You've described age as a factor that can impact how degraded a DNA sample is, correct?

6 DR. GERDES:

Yes.

7 MR. CLARKE:

That's not the only factor that impacts that, is it?

8 DR. GERDES:

No. There are multiple factors involved.

9 MR. CLARKE:

The substrate, the surface that a stain is on can impact it?

10 DR. GERDES:

That's possible.

11 MR. CLARKE:

The way a sample is packaged let's say after it's collected?

12 DR. GERDES:

That's possible.

13 MR. CLARKE:

Whether the sample is collected in a relatively wetter or drier state impacts that rate of degradation?

14 DR. GERDES:

That's true.

15 MR. CLARKE:

And temperature can impact that rate of degradation as well?

16 DR. GERDES:

True.

17 MR. CLARKE:

So those are a series or at least five or six, four or five or six examples of factors that can affect how a sample degrades and at what rate?

18 DR. GERDES:

Correct.

19 MR. CLARKE:

Now, you've described, Dr. Gerdes, your opinion that 28 percent of the time, that there was a contaminant in your examination of the LAPD PCR typing that was not shown in the negative control?

20 DR. GERDES:

Correct.

21 MR. CLARKE:

Now, that is dependent on how you've used the term "Contaminant" through all of your review of that material, correct?

22 DR. GERDES:

Correct.

23 MR. CLARKE:

That includes dots or reactions from the various types that are less than the C dot, correct?

24 DR. GERDES:

Correct.

25 MR. CLARKE:

And, in fact, from your review of the LAPD, that includes a very large number of samples that in fact had reactions that you classified as a contaminant that were less than the C dot, correct?

26 DR. GERDES:

That's correct.

27 MR. CLARKE:

In fact, that C dot is very important in interpreting results, correct?

28 DR. GERDES:

It's important in interpreting a single sample known to be from a known individual.

29 MR. CLARKE:

Is there any instance in this case in which a dot is called as a genuine result where it's less than the C dot?

30 DR. GERDES:

I don't recall. I think there are some that are very close in terms of my interpretation versus theirs and from looking at the strips.

31 MR. CLARKE:

In this case, as to the results--and I'm sorry. Your answer is, you don't recall, but you think there may have been?

32 DR. GERDES:

I think there may have been.

33 MR. CLARKE:

As far as samples that are called, again, in this case, isn't the fact that reactions are at the C dot or higher very important in determining the accuracy of results?

34 DR. GERDES:

I've expressed my opinion on that.

35 MR. CLARKE:

Well, I'm sorry, Dr. Gerdes. What my question is to you is, isn't it a fact in calling results in this case, whether those results are at or above the C dot is in fact very important in calling DQ-Alpha results?

36 DR. GERDES:

It's important in determining that you have a minimum amount of DNA, yes.

37 MR. CLARKE:

And, in fact, that's just what the user guide recommends, isn't it?

38 DR. GERDES:

Yes.

39 MR. CLARKE:

It's what the package insert, that little insert that comes with the kits recommends also, isn't it?

40 DR. GERDES:

Yes.

41 MR. CLARKE:

And in fact, it's what Gary Sims followed in this case, isn't it?

42 DR. GERDES:

Yes.

43 MR. CLARKE:

What Renee Montgomery followed in this case?

44 DR. GERDES:

Yes.

45 MR. CLARKE:

It's what Robin Cotton and Paula Yates and Julie Cooper followed in this case, correct?

46 DR. GERDES:

Yes.

47 MR. CLARKE:

It's what Collin Yamauchi followed in this case?

48 DR. GERDES:

Yes.

49 MR. CLARKE:

As far as these kits from Roche, you don't have any complaints with Roche about the quality of the kits they manufacture, do you?

50 DR. GERDES:

No.

51 MR. CLARKE:

They manufacture the DQ-Alpha kit?

52 DR. GERDES:

Yes.

53 MR. CLARKE:

The D1S80 kit?

54 DR. GERDES:

Yes.

55 MR. CLARKE:

The polymarker kit?

56 DR. GERDES:

Yes.

57 MR. CLARKE:

And, in fact, you use your own kit for--well, let me rephrase that. You use the Roche manufactured kit to test chlamydia in clinical casework, correct?

58 DR. GERDES:

That's correct.

59 MR. CLARKE:

Now, earlier, you described the fact that in your opinion, contamination at the LAPD was predominately in the reagent extraction controls. Do you recall that?

60 DR. GERDES:

Yes.

61 MR. CLARKE:

And you used the term "At early stages," that is at early stages in the DNA typing process; is that right?

62 DR. GERDES:

That's correct.

63 MR. CLARKE:

Where is that shown--let me rephrase that. As far as contamination shown in the early phases or early stages in this case, where is that shown in the controls that were run in this case?

64 DR. GERDES:

The substrate controls were clean in this particular case.

65 MR. CLARKE:

Well, weren't the other controls negative as well in this case?

66 DR. GERDES:

The two reference samples showed evidence of cross-contamination. Other than that, the other controls were clean.

67 MR. CLARKE:

Reagent blanks?

68 DR. GERDES:

Yes.

69 MR. CLARKE:

Positive amplification controls?

70 DR. GERDES:

Yes.

71 MR. CLARKE:

Negative amplification controls?

72 DR. GERDES:

Yes.

73 MR. CLARKE:

Quality control samples?

74 DR. GERDES:

Yes.

75 MR. CLARKE:

Aren't the fact that those controls all operated properly, isn't that extremely an important fact in evaluating the reliability of the results in this case?

76 DR. GERDES:

In this particular case, you're dealing with very degraded samples and with low levels of DNA. It introduces a new situation in terms of how well those controls would be expected to work as we discussed on direct exam.

77 MR. CLARKE:

But again, isn't the evaluation of all those controls central to interpreting the accuracy of results using any PCR marker?

78 DR. GERDES:

They have a bearing on that, yes.

79 MR. CLARKE:

They have a very important bearing, don't they?

80 DR. GERDES:

Yes.

81 MR. CLARKE:

Now, what you've described earlier this afternoon as substantial errors at the LAPD, was that in reference to the five errors that you allege the LAPD made in typing?

82 DR. GERDES:

Yes.

83 MR. CLARKE:

So that wasn't--your comment about substantial errors wasn't related to anything other than those five alleged errors that were discussed during cross-examination as well, correct?

84 DR. GERDES:

I was referring to the five errors and the fact they have substantial contamination that persists.

85 MR. CLARKE:

It's your opinion that PCR shouldn't be used in forensics at all, correct?

86 DR. GERDES:

Until this problem is solved in terms of getting a handle on working with these types of specimens and the difficulties of the cross-contamination and other kinds of contamination problems, that's my opinion, yes.

KEY QUOTE
87 MR. CLARKE:

Shouldn't be used to include people?

88 DR. GERDES:

That's correct.

89 MR. CLARKE:

Shouldn't be used to exclude people?

90 DR. GERDES:

That's correct.

91 MR. CLARKE:

And, Dr. Gerdes, the opinion you offer about PCR and the fact that in your opinion, it shouldn't be used, you offer that opinion whether or not there are RFLP results based on the same sample?

92 DR. GERDES:

That's correct.

93 MR. CLARKE:

Can I have just a moment, your Honor?

94 THE COURT:

Certainly.

95 (Discussion held off the record between the Deputy District Attorneys.)
96 MR. CLARKE:

Thank you. Nothing further, your Honor.

97 THE COURT:

Mr. Scheck.

FURTHER REDIRECT EXAMINATION BY MR. SCHECK

98 MR. SCHECK:

Dr. Gerdes, Mr. Clarke asked you if there were tests that you performed in this case to confirm a hypothesis of cross-contamination. Do you recall that?

99 DR. GERDES:

Yes.

100 MR. SCHECK:

If the Rockingham glove and Bundy blood drops were cross-contaminated in the evidence processing room on June 14th, is there any kind of a test that you can think of that can prove that now?

101 MR. CLARKE:

Objection. Assumes facts not in evidence.

102 THE COURT:

Overruled.

103 DR. GERDES:

No. At this point, it's essentially the same DNA. It's been transferred physically, and from that point on, there's nothing you can do, any kind of analysis that would allow you to determine that that's the reason that that DNA is on that sample.

KEY QUOTE
104 MR. SCHECK:

He asked you questions about tests to determine levels of bacterial degradation. Do you recall that?

105 DR. GERDES:

Yes.

106 MR. SCHECK:

Were yield gels done in this case?

107 DR. GERDES:

Yes.

108 MR. SCHECK:

Did Gary Sims render an opinion about what the yield gel showed in this case?

109 DR. GERDES:

Yes.

110 MR. SCHECK:

What do the yield gels tell us about samples 48, 49, 50 and 52?

111 DR. GERDES:

They're degraded, significantly degraded.

112 MR. SCHECK:

By bacteria?

113 DR. GERDES:

By--yes.

114 MR. SCHECK:

The--you were asked questions about the bloodstains on the back gate that were collected on July 3rd versus the Bundy blood drops that were collected on June 13th. Do you recall those?

115 DR. GERDES:

Yes.

116 MR. SCHECK:

Now, is it your understanding that all those samples were originally dry when collected?

117 DR. GERDES:

No.

118 MR. SCHECK:

Well, were the Bundy blood drops dry before they were swatched with wet swatches?

119 DR. GERDES:

No. They were wet.

120 MR. SCHECK:

The back gate, what about that?

121 DR. GERDES:

They--they--I'm not--they presumably were dry.

122 MR. SCHECK:

And if you put once--whether wet or dry, if you swatch the sample with a wet swatch--

123 DR. GERDES:

Yes.

124 MR. SCHECK:

--and put it in a plastic bag, is that what begins the process of degradation?

125 DR. GERDES:

Yes. They're now all wet.

126 MR. SCHECK:

And in terms of these stains on the back gate--you've read the demonstration papers in regard to the effects of environmental conditions?

127 DR. GERDES:

Yes.

128 MR. SCHECK:

On bloodstains?

129 DR. GERDES:

Yes.

130 MR. SCHECK:

In your judgment, are those the rigorous scientific studies?

131 DR. GERDES:

I don't--I'm not convinced they're rigorous, but they deal with the kinds of things that possibly could cause degradation.

132 MR. SCHECK:

But in terms of their demonstrations, do they demonstrate that sunlight on a bloodstain over time causes degradation?

133 DR. GERDES:

Yes.

134 MR. SCHECK:

Does it indicate that exposure to moisture and other environmental insults over time on a bloodstain causes degradation?

135 DR. GERDES:

Yes.

136 MR. SCHECK:

In terms of your microbiology background, would you expect that there would be degradation on stains over time that were exposed to sunlight, moisture and other environmental insults?

137 DR. GERDES:

Yes.

138 MR. SCHECK:

Were--in terms of location, were samples 50 and 117 separated by more than a few feet?

139 DR. GERDES:

They didn't appear to be, no.

140 MR. SCHECK:

Now, you were asked a whole series of questions about the relevance of the C dot. What is your opinion about the relevance of the C dot when interpreting mixtures?

141 MR. CLARKE:

Objection. No foundation.

142 THE COURT:

Sustained.

143 MR. SCHECK:

Well, in terms of a control, when interpreting a DQ-Alpha strip with a mixed sample--withdrawn. Mr. Clarke asked you questions about the C dot being a very important control. Do you recall those?

144 DR. GERDES:

Yes.

145 MR. SCHECK:

And your answer was, it's an important control when you're dealing with a known--one known sample, correct?

146 DR. GERDES:

Correct.

147 MR. SCHECK:

All right. When dealing with a mixture, what is the relevance of the C dot as a control?

148 DR. GERDES:

It simply states that there's enough DNA there to type, but when there's a mixture, you can't interpret how much of that DNA is from the first contributor or individual and how much is from the second. And so the intensity of the dots become irrelevant.

149 MR. SCHECK:

So the intensity--when you're dealing with the mixture, the intensity of dots relative to the C dot, what is the relevance of that in your opinion?

150 DR. GERDES:

It's irrelevant.

151 MR. SCHECK:

Now--and in the user guide, do they say in a mixture, that you should interpret that the same way you interpret a single source sample in relation to the C dot?

152 DR. GERDES:

No. They state you should be extremely cautious when you are dealing with mixtures or--

153 MR. SCHECK:

Not a clean bill of health?

154 DR. GERDES:

That's correct.

155 MR. SCHECK:

You go further in your judgment?

156 DR. GERDES:

Correct.

157 MR. SCHECK:

Without bringing the boards back up again, with respect to the 1.3 dots, the faint 1.3 dots on the Bronco sample, on item 31, and the 1.3 dots on LAPD item 52, does development time as illustrated by those boards, is that a factor in terms of the intensity of the dots?

158 DR. GERDES:

Yes. By developing that longer, the dot becomes more intense.

159 MR. SCHECK:

So what is the window of development length at DOJ?

160 DR. GERDES:

20 or 30 minutes.

161 MR. SCHECK:

If they develop it longer, the dot becomes more intense?

162 DR. GERDES:

Yes.

163 MR. SCHECK:

Less--shorter period, less intense?

164 DR. GERDES:

Yes.

165 MR. SCHECK:

What about the controls in those samples? What is the purpose of a positive control when running a series of experiments like that?

166 DR. GERDES:

Well, if you have any indication of dots or human DNA or artifacts that shouldn't be there, you can't--you should not interpret that result.

167 MR. SCHECK:

Is the expression in science "Controls failing"?

168 DR. GERDES:

Yes. The controls fail.

169 MR. SCHECK:

If the controls fail, is it scientifically correct in any kind of scientific experiment to call the results?

170 DR. GERDES:

No, it's not correct.

171 MR. SCHECK:

Did the controls fail with respect to item 31?

172 DR. GERDES:

Yes.

173 MR. SCHECK:

Now, I ask that these two documents be marked Defendant's next in order.

174 THE COURT:

1315.

175 MR. SCHECK:

I'm sorry?

176 THE COURT:

1315.

177 MR. SCHECK:

1315 and 1316. Well, actually, your Honor, maybe we can make the first one 1315-A and the other one 1315-B.

178 THE COURT:

Okay.

179 MR. SCHECK:

Thank you.

180 (Deft's 1315-A and 1315-B for id = documents)
181 MR. SCHECK:

Now, Mr. Clarke handed you some typing sheets from casework that you had never seen before?

182 DR. GERDES:

That's correct.

183 MR. SCHECK:

All right.

184 THE COURT:

I don't think that was the testimony.

185 MR. SCHECK:

Had you ever seen those two sheets before?

186 DR. GERDES:

No. Well, I may have seen them while I was at the laboratory. I didn't have them in my documents here.

187 MR. SCHECK:

Were they produced for you?

188 DR. GERDES:

They were produced for me, yes.

189 MR. SCHECK:

Were those two sheets produced for you initially by LAPD in discovery?

190 DR. GERDES:

They weren't sent to me specifically.

191 MR. SCHECK:

I'm not talking about 1315-A and B.

192 DR. GERDES:

No. I know. I may have seen them at or looked--glanced at them while I was at the laboratory. They were not a document that I requested on discovery. It was not provided to me to look at at a later time.

193 MR. SCHECK:

And were a series of these documents initially provided to you in discovery?

194 DR. GERDES:

Yes.

195 MR. SCHECK:

Now, this is Defendant's 1295. Do those two pieces of paper that Mr. Clarke showed you in any way change your opinion about the level of contamination that you found on runs at the Los Angeles Police Department between May of 1993 and August of 1994?

196 DR. GERDES:

No, they don't. Those were all evidence items and they weren't something I would have considered in the analysis.

197 MR. SCHECK:

Now, putting 1315--what are 1315-A and B?

198 DR. GERDES:

These are two pages that were just provided on discovery. One was discovered with the first batch of discovery and the second was subsequently provided again at a different date.

199 MR. SCHECK:

And what does 1315-A, the one you indicated that was first provided, show?

200 MR. SCHECK:

Please come back.

201 DR. GERDES:

It shows a series of strips and then some of the strips, 1 through 4, have been blocked off. At that time, a number of strips were blocked off like this, and it was explained to me that this is because they were evidence items.

KEY QUOTE
202 MR. SCHECK:

What is 1315-B?

203 DR. GERDES:

This is the same page on a subsequent discovery when--this time, they're not blocked off and the first item is a control swatch.

204 MR. SCHECK:

And what does that show in terms of contamination?

205 DR. GERDES:

It's contaminated with a 4 dot.

206 MR. SCHECK:

Were you dependent upon what was provided to you in terms of the materials about what you got from the LAPD people when you made your request?

207 DR. GERDES:

Yes.

208 MR. SCHECK:

No further questions, your Honor.

209 THE COURT:

Mr. Clarke.

210 MR. CLARKE:

Yes. Could I have just a moment, your Honor?

211 (Brief pause.)
212 MR. CLARKE:

Dr. Gerdes, with regard to that particular set of samples that you just placed on the board, that involved a control, correct?

213 DR. GERDES:

Yes.

214 MR. CLARKE:

And, in fact, on your chart, you note that control as having what you characterize as a contaminant, correct?

215 DR. GERDES:

Yes. Based on the second batch of discovery that I received.

216 MR. CLARKE:

And that was in January of 1995?

217 DR. GERDES:

I believe so, yes. Well, actually that was--that particular item was mailed to me before that, sometime in December.

218 MR. CLARKE:

Where you were able to see all of the samples?

219 DR. GERDES:

On the second batch, yes.

220 MR. CLARKE:

And that was in January?

221 DR. GERDES:

Either December or January, yes.

222 MR. CLARKE:

So you've had that sample with all of the samples shown for at least seven months?

223 DR. GERDES:

Yes.

224 MR. CLARKE:

And, in fact, both of the charts that you provided to the People both show that particular sample as one of your alleged instances of contamination, correct?

225 DR. GERDES:

Yes. The point is that it was blocked off the first time I received it and only through discovery being able to see all of the unblocked off materials--

226 MR. CLARKE:

Objection. Move to strike. Not responsive.

227 THE COURT:

Sustained. The answer is stricken.

228 MR. CLARKE:

Dr. Gerdes, what I'm asking you is, didn't you have an opportunity to see that at least seven months ago?

229 DR. GERDES:

Yes.

230 MR. CLARKE:

And, in fact, you got to see all of the strips that were in the binders at the LAPD, correct, DQ-Alpha strips?

231 DR. GERDES:

Correct.

232 MR. CLARKE:

You had an opportunity to see the polymarker strips, but elected not to review them; is that right?

233 DR. GERDES:

That's correct. LAPD didn't do polymarker for this case.

234 MR. CLARKE:

But don't those polymarker strips have negative controls also?

235 DR. GERDES:

Yes.

236 MR. SCHECK:

Your Honor, I think this is beyond the scope.

237 THE COURT:

It is.

238 MR. CLARKE:

Now, as far as item no. 117, Dr. Gerdes, you don't know how much was in that sample when it was left there, do you, how much DNA?

239 DR. GERDES:

No.

240 MR. CLARKE:

And, in fact, 117 can be a degraded sample, can't it?

241 DR. GERDES:

According to the check gel, the yield gel, it's not degraded to the degree that the others are.

242 MR. CLARKE:

But it is degraded, isn't it?

243 DR. GERDES:

There's some degree of degradation on any of these samples.

244 MR. CLARKE:

Now, with respect to items 47 through 50 and 52, they were stored in plastic bags, correct?

245 DR. GERDES:

Correct.

246 MR. CLARKE:

They were left in a truck for some time; is that correct?

247 DR. GERDES:

Correct.

248 MR. CLARKE:

And, in fact, they were in a wet state while they were stored in those plastic bags in a truck, correct?

249 DR. GERDES:

Correct.

250 MR. CLARKE:

To your knowledge, did that occur for a number of hours?

251 DR. GERDES:

Yes.

252 MR. CLARKE:

With regard to 117, that's not the same case, is it?

253 DR. GERDES:

I'd--a lot of those details are--I'm not aware of the details on that second set--that second time they did this.

254 MR. CLARKE:

I'd like you to assume hypothetically that when 115, 116 and 117 were collected, they were placed in plastic bags and, in fact, they were recovered from those plastic bags at a time much less than was the case with the Bundy blood drops.

255 MR. SCHECK:

Objection. Based on no evidence in this case.

256 THE COURT:

Vague.

257 (Discussion held off the record between the Deputy District Attorneys.)
258 MR. CLARKE:

As far as the time that samples may spend in plastic bags when they're collected, wouldn't it be a factor how many evidence items were collected at the same time, whether it's one or two others or whether it's perhaps 30, 40--30 or 40 other stains. Would that be important in terms of how much time that wet blood spent in a plastic bag?

259 DR. GERDES:

If I understand your question correctly, you're asking me if it would make a difference if there was one swatch or 50 swatches in the same plastic bag, is that what you're saying, as opposed to all in different bags?

260 MR. CLARKE:

No. The actual collection of a number of items so that the evidence collector would have to spend more time in the collection process.

261 DR. GERDES:

In the collection process?

262 THE COURT:

I don't know that this is an appropriate question for Dr. Gerdes.

263 MR. CLARKE:

I'm sorry, your Honor?

264 THE COURT:

I don't know that that's an appropriate question for this witness.

265 MR. CLARKE:

Would you agree that the less time that a particular item spent in a plastic bag in a wet state, the more likely that sample would contain more DNA?

266 DR. GERDES:

That's probably true.

267 (Discussion held off the record between the Deputy District Attorneys.)
268 MR. CLARKE:

Would you agree that, in fact, that could account for in this case the difference in DNA amounts in 117 versus 47 through 50 and 52?

269 MR. SCHECK:

Objection. Speculation, based on no evidence.

270 THE COURT:

Sustained.

271 (Discussion held off the record between the Deputy District Attorneys.)
272 MR. CLARKE:

As far as these number of factors that can account for differences in DNA levels, you would agree, would you not, that the time spent in those bags would be an important factor?

273 DR. GERDES:

It would be one factor that's important, yes.

274 MR. CLARKE:

All right. Thank you. Nothing further, your Honor.

275 MR. SCHECK:

Just briefly.

FURTHER REDIRECT EXAMINATION BY MR. SCHECK

276 MR. SCHECK:

Showing you what's 1165. Mr. Clarke has been asking you if you know the amount of blood to start with on 47, 48, 50, 52, 115, 116, 117, right?

277 DR. GERDES:

Correct.

278 MR. SCHECK:

Does anybody know?

279 DR. GERDES:

Nobody knows.

280 MR. SCHECK:

Is there any test that can tell us exactly how much there was at the beginning?

281 DR. GERDES:

No.

282 MR. SCHECK:

Now, in terms of the amounts of high molecular weight DNA, there's 1165 based on a hypothetical chart, subsequently the bar chart. Does that reflect the comparative amounts of high molecular weight human DNA in the Bundy blood drops as opposed to 117?

283 DR. GERDES:

It does.

284 MR. SCHECK:

Showing 1192-A and B. Let's start with A. Do you recall seeing this chart introduced through the testimony of Gary Sims indicating a comparison of the concentration of 117 compared to the other samples?

285 DR. GERDES:

Yes.

286 MR. SCHECK:

Do you agree with it?

287 DR. GERDES:

Yes.

288 MR. SCHECK:

Does it indicate that 117 is much more concentrated than the other samples?

289 DR. GERDES:

Yes.

290 MR. SCHECK:

Does it indicate 115 and 116 are more concentrated than the other samples?

291 DR. GERDES:

Yes.

292 MR. SCHECK:

Do you know--you were asked about when these bloodstains were deposited on these locations, correct?

293 DR. GERDES:

Correct.

294 MR. SCHECK:

Do you know?

295 DR. GERDES:

No.

296 MR. CLARKE:

Excuse me. Objection. Beyond the scope.

297 THE COURT:

Overruled.

298 MR. CLARKE:

Also misstates the evidence.

299 THE COURT:

It does. It misstates the question.

300 MR. SCHECK:

I'm sorry.

301 MR. SCHECK:

Do you know when bloodstains 115, 116 and 117 were deposited?

302 DR. GERDES:

No.

303 MR. SCHECK:

You don't know if it was after June 13th?

304 DR. GERDES:

That's correct. I don't know that.

305 MR. SCHECK:

And you don't know if it came from blood that contained EDTA?

306 DR. GERDES:

That's true.

307 MR. SCHECK:

Nothing further.

308 THE COURT:

Mr. Clarke.

309 MR. CLARKE:

No further questions, your Honor.

310 THE COURT:

All right. Dr. Gerdes, thank you very much, sir. You may step down.

311 DR. GERDES:

Thank you.

312 THE COURT:

Next witness.

Temperature

tense

Key Quotes (5)

Dr. John Gerdes
No. At this point, it's essentially the same DNA. It's been transferred physically, and from that point on, there's nothing you can do, any kind of analysis that would allow you to determine that that's the reason that that DNA is on that sample.
Gerdes concedes there is no test that can prove cross-contamination occurred after the fact — a double-edged answer that validates the defense theory while also acknowledging its unprovability.
Dr. John Gerdes
It's irrelevant.
Gerdes's one-word answer on the relevance of dot intensity relative to the C dot when interpreting mixture samples — directly undercutting Clarke's earlier line establishing the C dot as 'very important.'
Dr. John Gerdes
Until this problem is solved in terms of getting a handle on working with these types of specimens and the difficulties of the cross-contamination and other kinds of contamination problems, that's my opinion, yes.
Clarke successfully established that Gerdes's anti-PCR position is categorical — it would exclude even exculpatory results — framing his opinions as extreme rather than case-specific.
Dr. John Gerdes
Nobody knows.
Scheck's redirect closed on Gerdes confirming that no one can determine how much blood was originally deposited at any location — undermining Clarke's argument that 117's higher concentration proves it was deposited legitimately.
Dr. John Gerdes
It shows a series of strips and then some of the strips, 1 through 4, have been blocked off... This time, they're not blocked off and the first item is a control swatch... It's contaminated with a 4 dot.
Gerdes explains how LAPD's initial discovery production concealed contaminated control samples by blocking them out, with the unredacted version (1315-B) revealing a contaminated control.

Evidence (8)

Defendant's 1315-A
LAPD typing sheet from first discovery production with strips 1-4 blocked out, concealing contaminated control swatches
introduced and discussed
Defendant's 1315-B
Same LAPD typing sheet from subsequent discovery production, unblocked — reveals control swatch contaminated with a 4 dot
introduced and discussed
Defendant's 1295
Gerdes's contamination chart summarizing LAPD PCR runs
referenced
1165
Bar chart showing comparative amounts of high molecular weight human DNA in Bundy blood drops versus back gate sample 117
discussed
1192-A and 1192-B
Gary Sims chart comparing concentration of sample 117 against other Bundy and back gate samples
discussed; Gerdes agreed with its conclusions
Informal
LAPD items 47, 48, 49, 50, 52 (Bundy blood drops) — stored wet in plastic bags in a truck
discussed in context of degradation
+ 2 more

Notable Exchanges (5)

George ClarkeDr. John Gerdes
Clarke extracted Gerdes's categorical position that PCR should not be used in forensics to include or exclude anyone — even when RFLP results exist on the same sample — framing the defense's DNA expert as an absolutist whose opinion would invalidate exculpatory DNA evidence too.
strategic
Barry ScheckDr. John Gerdes
Scheck rehabilitated the C dot issue by having Gerdes explain that while the C dot matters for single-source samples, it is 'irrelevant' when interpreting mixtures, because you cannot know what proportion of DNA came from each contributor.
strategic
Barry ScheckDr. John Gerdes
Scheck introduced 1315-A and 1315-B to show that LAPD's initial discovery production blocked out contaminated control strips, with the unredacted version revealing a 4-dot contamination on a control swatch — suggesting concealment in discovery.
revealing
George ClarkeDr. John Gerdes
Clarke attempted to use the 1315 documents against Gerdes, pointing out he had access to the full unblocked materials for at least seven months before trial — implying he had ample time to address them in his analysis.
impeaching
George ClarkeLance A. Ito
Clarke tried to introduce a hypothetical about whether 117's higher DNA concentration could be explained by collection logistics (fewer items collected, less time wet in plastic), but the judge twice found the questions vague or inappropriate for this witness.
frustrated

Credibility Attacks (3)

⚔ Dr. John Gerdes
scope and extremity of opinion
Clarke established that Gerdes's anti-PCR opinion is categorical — extending even to exclusions and to cases with corroborating RFLP results — attempting to portray him as an outlier whose testimony would, if accepted, invalidate all forensic PCR evidence.
⚔ Dr. John Gerdes
prior access to evidence
Clarke pointed out that Gerdes had the unblocked 1315 discovery materials for at least seven months before testifying, undermining any suggestion that the document was a surprise or that LAPD concealed it from him.
⚔ LAPD crime laboratory
discovery document showing concealment
Scheck used 1315-A versus 1315-B to suggest that LAPD initially blocked out contaminated control strips in their first discovery production, with the contamination only visible once unredacted materials were later provided.

Objections

8 objections (5 sustained, 2 overruled)
Proceeding 7197 • 312 utterances • Defense witness
Criminal Trial
Department 103
⚖️ Start
📂 AUG 7, 1995 📄 Recross-examination of Dr. Joh
AUG 7, 1995 KRT DvH TD